Inhibition of Passive Localized Experimental Allergic Encephalomyelitis by InterferonAbreu S.L.a · Tondreau J.a · Levine S.b · Sowinski R.b
aDepartment of Biological Sciences, Fordham University, Bronx, N. Y.; bPathology Department, New York Medical College, Valhalla, N.Y., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Recently it has been reported that interferon (IFN) suppresses experimental allergic encephalomyelitis (EAE) in actively immunized Lewis rats. In the present study the effect of IFN on a localized form of passively transferred EAE has been investigated. Localization and acceleration of the disease was obtained by injection of EAE lymph node cells into rats which had, 3 days previously, been prepared with a thermal brain injury. Within 24 h of cell transfer perivenular lymphocytic infiltrates (EAE lesions) were observed in the brain. Administration of IFN (40,000 U/kg) right after EAE lymph node cell injection resulted in a significant reduction or elimination of EAE lesions. The possibility that IFN is acting exclusively on the afferent arc is eliminated, and the results suggest that IFN may be acting, although not solely, through modulations of components of the efferent arc. IFN was equally effective in suppressing EAE in adrenalectomized animals. This demonstrates that the immunosuppressive effects observed in this study are not due to endogenously produced corticosteroids.
© 1983 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.